Foreign Firms Among Casualties As China FDA Clears Clinical Data Smog
This article was originally published in PharmAsia News
Although products from foreign pharma companies in general are considered to be of high quality in China, a number of such firms, including India’s Sun Pharma, have retracted product registration applications as regulatory authorities widen a crackdown on the quality of the clinical data included in such filings.
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.